MARKET

BLUE

BLUE

Bluebird Bio Inc
NASDAQ
7.27
+0.02
+0.28%
After Hours: 7.45 +0.18 +2.48% 19:37 02/14 EST
OPEN
7.30
PREV CLOSE
7.25
HIGH
7.54
LOW
7.02
VOLUME
183.83K
TURNOVER
--
52 WEEK HIGH
38.40
52 WEEK LOW
5.80
MARKET CAP
70.68M
P/E (TTM)
-0.1973
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BLUE last week (0210-0214)?
Weekly Report · 13h ago
Weekly Report: what happened at BLUE last week (0203-0207)?
Weekly Report · 02/10 09:11
Fulcrum: Next Set Of SCD Data Is Crucial For Continued Pipeline Advancement
Seeking Alpha · 02/07 22:59
Weekly Report: what happened at BLUE last week (0127-0131)?
Weekly Report · 02/03 09:11
Weekly Report: what happened at BLUE last week (0120-0124)?
Weekly Report · 01/27 09:12
Weekly Report: what happened at BLUE last week (0113-0117)?
Weekly Report · 01/20 09:11
Weekly Report: what happened at BLUE last week (0106-0110)?
Weekly Report · 01/13 09:11
Bluebird Bio price target lowered to $8 at RBC Capital on ‘limited cash runway’
TipRanks · 01/07 13:46
More
About BLUE
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. It markets three gene therapies: ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel), SKYSONA (elivaldogene autotemcel, also known as eli-cel), and LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel). ZYNTEGLO is the first gene therapy for the treatment of adult and pediatric patients with ß-thalassemia who require regular red blood cell transfusions. SKYSONA is used to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). LYFGENIA was approved by the FDA for the treatment of patients 12 years of age or older with sickle cell disease (SCD) and a history of vaso-occlusive events (VOEs). It is focused on pursuing curative gene therapies.

Webull offers bluebird bio Inc stock information, including NASDAQ: BLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BLUE stock methods without spending real money on the virtual paper trading platform.